Acute myeloid leukemia with mutated nucleophosmin (NPM1): Molecular, pathological, and clinical features

Cancer Treatment and Research

Volumn 145, Issue , 2010, Pages 149-168

  Falini, Brunangelo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; NUCLEOPHOSMIN; PROTEIN P53; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; CENTROSOME; CLINICAL FEATURE; EXON; GENE DUPLICATION; GENE MUTATION; GENE REPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMOGENESIS; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; RIBOSOME; WESTERN BLOTTING; ADULT; CHILD; CLASSIFICATION; FORECASTING; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; PROTEIN TRANSPORT;

ADULT; CENTROSOME; CHILD; EXONS; FORECASTING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RIBOSOMES; TUMOR SUPPRESSOR PROTEINS;

EID: 77956159563     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69259-3_9     Document Type: Review

References (118)

1. Albiero E, Madeo D, Bolli N, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia. 2007;21:1099-1103.
2. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106:899-902.
3. Ammatuna E, Noguera NI, Zangrilli D, et al. Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturingHPLC. Clin Chem. 2005;51:2165-2167.
4. Andersen JS, Lam YW, Leung AK, et al. Nucleolar proteome dynamics. Nature. 2005;433:77-83.
5. Apicelli AJ, Maggi LB, Jr, Hirbe AC, et al. A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function. Mol Cell Biol. 2008;28(3):1068-1080.
6. Bernard K, Litman E, Fitzpatrick JL, et al. Functional proteomic analysis of melanoma progression. Cancer Res. 2007;63:6716-6725.
7. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol. 2004;24:985-996.
8. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106:3618-3620.
9. Bolli N, Galimberti S, Martelli MP, et al. Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. Lancet Oncol. 2006;7:350-352.
10. Bolli N, Nicoletti I, De Marco MF, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res. 2007;67:6230-6237.
11. Borer RA, Lehner CF, Eppenberger HM, et al. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56:379-390.
12. Budhu AS, Wang XW. Loading and unloading: orchestrating centrosome duplication and spindle assembly by Ran/Crm1. Cell Cycle. 2005;4:1510-1514.
13. Caudill JS, Sternberg AJ, Li CY, et al. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol. 2006;133:638-641.
14. Cazzaniga G, DellOro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106:1419-1422.
15. Chan PK, Chan FY. Nucleophosmin/B23 (NPM) oligomer is a major and stable entity in HeLa cells. Biochim Biophys Acta. 1995;1262:37-42.
16. Chan PK, Liu QR, Durban E. The major phosphorylation site of nucleophosmin (B23) is phosphorylated by a nuclear kinase II. Biochem J. 1990;270:549-552.
17. Chan WY, Liu QR, Borjigin J, et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry. 1989;28:1033-1039.
18. Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res. 2006;66:3310-3316.
19. Chou YH, Yung BY. Cell cycle phase-dependent changes of localization and oligomerization states of nucleophosmin/B23. Biochem Biophys Res Commun. 1995;217:313-325.
20. Colombo E, Bonetti P, Lazzerini Denchi E, et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol. 2005;25:8874-8886.
21. Colombo E, Marine JC, Danovi D, et al. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4:529-533.
22. Colombo E, Martinelli P, Zamponi R, et al. Delocalization and destabilization of the Arf tumor suppressor by the leukemia-associatedNPM mutant. Cancer Res. 2006;66:3044-3050.
23. Cordell JL, Pulford KA, Bigerna B, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood. 1999;93:632-642.
24. Dalenc F, Drouet J, Ader I, et al. Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells. Int J Cancer. 2002;100:662-668.
25. den Besten W, Kuo ML, Williams RT, et al. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle. 2005;4:1593-1598.
26. Dergunova NN, Bulycheva TI, Artemenko EG, et al. A major nucleolar protein B23 as a marker of proliferation activity of human peripheral lymphocytes. Immunol Lett. 2002;83:67-72.
27. Dingwall C, Dilworth SM, Black SJ, et al. Nucleoplasmin cDNA sequence reveals polyglutamic acid tracts and a cluster of sequences homologous to putative nuclear localization signals. EMBO J. 1987;6:69-74.
28. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740-3746.
29. Eirin-Lopez JM, Frehlick LJ, Ausio J. Long-term evolution and functional diversification in the members of the nucleophosmin/nucleoplasmin family of nuclear chaperones. Genetics. 2006;173:1835-1850.
30. Falini B. Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities? Leuk Lymphoma. 2007;48:2093-2095.
31. Falini B, Albiero E, Bolli N, et al. Aberrant cytoplasmic expression of C-terminaltruncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia. 2007;21:2052-2054; author reply 2054; discussion 2055-2056.
32. Falini B, Bolli N, Shan J, et al. Both carboxy-terminus NES motif and mutated tryptophan( s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood. 2006;107:4514-4523.
33. Falini B, Lenze D, Hasserjian R, et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia. 2007;21:1566-1570.
34. Falini B, Martelli M, Mecucci C, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ AML in SCID mice. Haematologica. 2008;93(5):775-779.
35. Falini B, Martelli MP, Bolli N, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood. 2006;108:1999-2005.
36. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood. 2002;99:409-426.
37. Falini B, Mecucci C, Saglio G, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 AML patients. Haematologica. 2008;93(3):439-442.
38. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266.
39. Falini B, Nicoletti I, Bolli N, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica. 2007;92:519-532.
40. Falini B, Nicoletti I, Martelli MF, et al. Acute myeloid leukemia carrying cytoplasmic/ mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109:874-885.
41. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999;94:3509-3515.
42. Fenaux P, Jonveaux P, Quiquandon I, et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood. 1991;78:1652-1657.
43. Feuerstein N, Chan PK, Mond JJ. Identification of numatrin, the nuclear matrix protein associated with induction of mitogenesis, as the nucleolar protein B23. Implication for the role of the nucleolus in early transduction of mitogenic signals. J Biol Chem. 1988;263:10608-10612.
44. Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
45. Gallagher R. Dueling mutations in normal karyotype AML. Blood. 2005;106:3681-3682.
46. Gjerset RA, Bandyopadhyay K. Regulation of p14ARF through subnuclear compartmentalization. Cell Cycle. 2006;5:686-690.
47. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature. 2003;426:895-899.
48. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437:147-153.
49. Grisendi S, Mecucci C, Falini B, et al. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6:493-505.
50. Hayami R, Sato K,Wu W, et al. Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer Res. 2005;65:6-10.
51. Herrera JE, Correia JJ, Jones AE, et al. Sedimentation analyses of the salt-and divalent metal ion-induced oligomerization of nucleolar protein B23. Biochemistry. 1996;35: 2668-2673.
52. Herrera JE, Savkur R, Olson MO. The ribonuclease activity of nucleolar protein B23. Nucleic Acids Res. 1995;23:3974-3979.
53. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem. 2000;275:24451-24457.
54. Hsu CY, Yung BY. Down-regulation of nucleophosmin/B23 during retinoic acidinduced differentiation of human promyelocytic leukemia HL-60 cells. Oncogene. 1998;16:915-923.
55. Huang N, Negi S, Szebeni A, et al. Protein NPM3 interacts with the multifunctional nucleolar protein B23/nucleophosmin and inhibits ribosome biogenesis. J Biol Chem. 2005;280:5496-5502.
56. Jones CE, Busch H, Olson MO. Sequence of a phosphorylation site in nucleolar protein B23. Biochim Biophys Acta. 1981;667:209-212.
57. Kuo ML, den Besten W, Bertwistle D, et al. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 2004;18:1862-1874.
58. Kurki S, Peltonen K, Laiho M. Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle. 2004;3:976-979.
59. Kurki S, Peltonen K, Latonen L, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell. 2004;5:465-475.
60. LamYW, Trinkle-Mulcahy L, LamondAI. The nucleolus.JCellSci. 2005;118:1335-1337.
61. Lambert B, Buckle M. Characterisation of the interface between nucleophosmin (NPM) and p53: potential role in p53 stabilisation. FEBS Lett. 2006;580:345-350.
62. Lee SY, Park JH, Kim S, et al. A proteomics approach for the identification of nucleophosmin and heterogeneous nuclear ribonucleoprotein C1/C2 as chromatin-binding proteins in response to DNA double-strand breaks. Biochem J. 2005;388:7-15.
63. Lingle WL, Salisbury JL. The role of the centrosome in the development of malignant tumors. Curr Top Dev Biol. 2000;49:313-329.
64. Liso A, Bogliolo A, Freschi V, et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia. 2008;22(6):1285-1289.
65. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064.
66. Ma Z, Kanai M, Kawamura K, et al. Interaction between ROCK II and Nucleophosmin/ B23 in the regulation of centrosome duplication. Mol Cell Biol. 2006;26:9016-9034.
67. Maiguel DA, Jones L, Chakravarty D, et al. Nucleophosmin sets a threshold for p53 response to UV radiation. Mol Cell Biol. 2004;24:3703-3711.
68. Mariano AR, Colombo E, Luzi L, et al. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal. Oncogene. 2006;25:4376-4380.
69. Morris SW,KirsteinMN, ValentineMB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkins lymphoma. Science. 1994;263: 1281-1284.
70. Mullighan CG, Kennedy A, Zhou X, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia. 2007;21:2000-2009.
71. Nakagawa M, Kameoka Y, R. S. Nucleophosmin in acute myelogenous leukemia (letter). N Engl J Med. 2005;352:1819-1820.
72. Namboodiri VM, Akey IV, Schmidt-Zachmann MS, et al. The structure and function of Xenopus NO38-core, a histone chaperone in the nucleolus. Structure. 2004;12:2149-2160.
73. Negi SS, Olson MO. Effects of interphase and mitotic phosphorylation on the mobility and location of nucleolar protein B23. J Cell Sci. 2006;119:3676-3685.
74. Nishimura Y, Ohkubo T, Furuichi Y, et al. Tryptophans 286 and 288 in the C-terminal region of protein B23.1 are important for its nucleolar localization. Biosci Biotechnol Biochem. 2002;66:2239-2242.
75. Nozawa Y, Van Belzen N, Van der Made AC, et al. Expression of nucleophosmin/B23 in normal and neoplastic colorectal mucosa. J Pathol. 1996;178:48-52.
76. Oki Y, Jelinek J, Beran M, et al. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 2006;91:1147-1148.
77. Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene. 2002;21: 6170-6174.
78. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000;103:127-140.
79. Okuwaki M. The structure and functions of NPM1/Nucleophsmin/B23, a multifunctional nucleolar acidic protein. J Biochem. 2008;143(4):441-448.
80. Okuwaki M, Matsumoto K, Tsujimoto M, et al. Function of nucleophosmin/B23, a nucleolar acidic protein, as a histone chaperone. FEBS Lett. 2001;506:272-276.
81. Okuwaki M, Tsujimoto M, Nagata K. The RNA binding activity of a ribosome biogenesis factor, nucleophosmin/B23, is modulated by phosphorylation with a cell cycledependent kinase and by association with its subtype. Mol Biol Cell. 2002;13:2016-2030.
82. Owens BM, Hawley RG. HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells. 2002;20:364-379.
83. Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood. 2006;108:4146-4155.
84. Peter M, Nakagawa J, Doree M, et al. Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase. Cell. 1990;60:791-801.
85. Quentmeier H, Martelli MP, Dirks WG, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005;19: 1760-1767.
86. Roti G, Rosati R, Bonasso R, et al. Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. J Mol Diagn. 2006;8:254-259.
87. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 2003;22:6068-6077.
88. Rubbi CP, Milner J. p53-guardian of a genomes guardian? Cell Cycle. 2003;2:20-21.
89. Ruggero D, Pandolfi PP. Does the ribosome translate cancer? Nat Rev Cancer. 2003;3:179-192.
90. Savkur RS, Olson MO. Preferential cleavage in pre-ribosomal RNA by protein B23 endoribonuclease. Nucl Acids Res. 1998;26:4508-4515.
91. Schmidt-Zachmann MS, Franke WW. DNA cloning and amino acid sequence determination of a major constituent protein of mammalian nucleoli. Correspondence of the nucleoplasmin-related protein NO38 to mammalian protein B23. Chromosoma. 1988;96:417-426.
92. Schmidt-Zachmann MS, Hugle-Dorr B, Franke WW. A constitutive nucleolar protein identified as a member of the nucleoplasmin family. EMBO J. 1987;6:1881-1890.
93. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733-3739.
94. Scholl S, Luftner J, Mugge LO, et al. Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia. Ann Hematol. 2007;86:763-765.
95. Scholl S, Mugge LO, Landt O, et al. Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia. Leuk Res. 2007;31:1205-1211.
96. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006;6:663-673.
97. Shiseki M, Kitagawa Y, Wang YH, et al. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leuk Lymphoma. 2007;48:2141-2144.
98. Spector DL, Ochs RL, Busch H. Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23. Chromosoma. 1984;90:139-148.
99. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106:2854-2861.
100. Swaminathan V, Kishore AH, Febitha KK, et al. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol Cell Biol. 2005;25:7534-7545.
101. Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 1999;8:905-912.
102. Tarapore P, Shinmura K, Suzuki H, et al. Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre-mRNA processing. FEBS Lett. 2006;580: 399-409.
103. Thiede C, Creutzig E, Illmer T, et al. Rapid and sensitive typing of NPM1 mutations using LNA-mediated PCR clamping. Leukemia. 2006;20:1897-1899.
104. Thiede C, Creutzig E, Reinhardt D, et al. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia. 2007;21:366-367.
105. Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107:4011-4020.
106. Tsui KH, Cheng AJ, Chang PL, et al. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology. 2004;64:839-844.
107. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747-3754.
108. Wang D, Baumann A, Szebeni A, et al. The nucleic acid binding activity of nucleolar protein B23.1 resides in its carboxyl-terminal end. J Biol Chem. 1994;269:30994-30998.
109. Wang W, Budhu A, Forgues M, et al. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol. 2005;7:823-830.
110. Wang D, Umekawa H, Olson MO. Expression and subcellular locations of two forms of nucleolar protein B23 in rat tissues and cells. Cell Mol Biol Res. 1993;39:33-42.
111. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood. 1994;84: 3148-3157.
112. Wu MH, Chang JH, Yung BY. Resistance to UV-induced cell-killing in nucleophosmin/ B23 over-expressed NIH 3T3 fibroblasts: enhancement of DNA repair and up-regulation of PCNA in association with nucleophosmin/B23 over-expression. Carcinogenesis. 2002;23:93-100.
113. Yao J, Fu C, Ding X, et al. Nek2A kinase regulates the localization of numatrin to centrosome in mitosis. FEBS Lett. 2004;575:112-118.
114. Yu Y, Maggi LB, Jr., Brady SN, et al. Nucleophosmin is essential for ribosomal protein L5 nuclear export. Mol Cell Biol. 2006;26:3798-3809.
115. Yun JP, Chew EC, Liew CT, et al. Nucleophosmin/B23 is a proliferate shuttle protein associated with nuclear matrix. J Cell Biochem. 2003;90:1140-1148.
116. Yung BY, Chan PK. Identification and characterization of a hexameric form of nucleolar phosphoprotein B23. Biochim Biophys Acta. 1987;925:74-82.
117. Zhang H, Shi X, Paddon H, et al. B23/nucleophosmin serine 4 phosphorylation mediates mitotic functions of polo-like kinase 1. J Biol Chem. 2004;279:35726-35734.
118. Zhang Y, Zhang M, Yang L, et al. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res. 2006;31:109-111.